Frequently Asked Questions

Eligibility depends on age. For ages 12–17, qualification is based on a BMI at or above the 95th percentile for age and sex (CDC pediatric growth charts). For ages 18–26, the standard adult threshold applies, a BMI of 30 or above. Our eligibility check takes about 2 minutes and gives you an immediate answer.

Thryvwell treats adolescents ages 12–17 and young adults ages 18–26. For adolescents, we follow the AAP clinical practice guidelines for pharmacotherapy in pediatric obesity. For young adults, we apply evidence-based adult weight management protocols with age-appropriate monitoring.

Thryvwell is entirely telehealth-based. All physician visits, guidance sessions, and check-ins happen virtually from home. This eliminates commute time, waiting rooms, and the stigma some teens feel visiting a weight management clinic. Lab work is done at a local facility near you.

Most families complete intake within 1–2 weeks of their eligibility check. The timeline depends on clinical review, prior authorization (if needed), and scheduling availability. Our team works to minimize wait times.

The initial eligibility check can be completed by a parent alone. The clinical intake appointment will include your child, as the physician needs to assess them directly. Some families prefer a parent-only pre-consultation to discuss approach before involving their teen.

Thryvwell serves patients across all 50 U.S. states. Because our care is delivered via telehealth, you can see your board-certified specialist from anywhere with an internet connection, no travel required.

A prescription alone isn't treatment; it's one component. Thryvwell provides the full clinical infrastructure: specialized pediatric clinicians, gradual dose titration, regular lab monitoring, growth tracking, nutrition guidance, behavioral support, and coordination with your child's pediatrician. This comprehensive approach is what clinical guidelines recommend.

Treatment duration varies by individual. Most families see meaningful results within 3–6 months. The clinical team works with your family to determine the appropriate duration based on your child's response, goals, and overall health trajectory. Treatment can be adjusted, paused, or discontinued at any time.

Yes. Your child's pediatrician stays informed throughout treatment. We provide regular updates on progress, lab results, and clinical decisions. Many families are referred to Thryvwell directly by their pediatrician.

The habits, nutrition patterns, and behavioral changes built during treatment create a foundation that persists beyond medication. We provide a structured step-down with gradual dose reduction and intensified lifestyle support to maintain progress long-term.

You can pause or discontinue treatment at any time. There are no long-term contracts or commitments. If the medication isn't the right fit, your clinical team will discuss alternative approaches and ensure a safe transition.

Yes. Semaglutide (Wegovy), the GLP-1 medication Thryvwell prescribes, has been FDA-approved for adolescents 12+ since December 2022, backed by the largest randomized controlled trials in adolescent populations, demonstrating a 16.1% reduction in BMI with a safety profile consistent with adults. Thryvwell prescribes only FDA-approved medications, never compounded alternatives. Every patient is supervised by a board-certified specialist with monthly visits, regular labs, and careful dose titration.

For patients under 18, this is exactly why Thryvwell exists. We built the only adolescent-specific protocol that monitors height velocity, bone density markers, and pubertal development at every visit. We track 12+ health markers related to adolescent growth because no adult weight-loss program was designed to do this. For young adults 18+, growth is typically complete, so the focus shifts to metabolic health, body composition, and long-term wellness.

GLP-1 medications are given as a once-weekly subcutaneous injection using a pre-filled pen device. It's a small, thin needle, similar to an EpiPen, and most teens report minimal discomfort. Your care team provides thorough injection training before the first dose.

Most side effects are mild and temporary (primarily nausea in the first few weeks). Your care team is available between appointments to address concerns. If side effects are significant, the physician can adjust dosing, timing, or medication. Treatment is always individualized.

Not necessarily. Treatment duration is individualized. Some adolescents achieve their health goals and successfully taper off medication with sustained lifestyle changes. Others benefit from longer-term treatment. Your clinical team will work with your family to determine the right approach over time.

Thryvwell's membership fee covers physician visits, nutrition guidance, habit support, and clinical monitoring. Medication cost is separate and depends on your insurance coverage. Many families pay significantly reduced rates for medication through manufacturer savings programs.

Coverage varies by plan. Many commercial insurance plans cover FDA-approved GLP-1 medications for adolescents with obesity when prescribed by a qualified physician. Our team handles prior authorization and appeals on your behalf. If coverage is denied, we help you access manufacturer savings programs.

Pharmaceutical companies offer patient assistance programs that can significantly reduce out-of-pocket medication costs. Eligible commercially insured patients may pay as little as $0–25 per month for their medication. Our team helps determine eligibility and assists with enrollment as part of the intake process.

We work with families regardless of insurance status. Manufacturer savings programs, patient assistance programs, and alternative medication options can make treatment accessible. Our team will discuss all available options during the intake process.